Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape

Listen to Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the role of testing for biomarkers and the current paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer.
Elena Gabriela Chiorean, MD
Philip Agop Philip, MD, PhD, FRCP
Released: October 26, 2021

Information on this Educational Activity


Philip Agop Philip, MD, PhD, FRCP

School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Philip Agop Philip, MD, PhD, FRCP, has disclosed that he has received funds for research support from Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Corcept, Halozyme, Incyte, Merck, NGM Bio, Novartis, Novocure, QED, Rafeal, Syncore, and Thyme; consulting fees from Blueprint, Erytech, Halozyme, Ipsen, Merck, QED, Rafael, Syncore, and TriSalus; and fees for non-CME/CE services from AstraZeneca, Bayer, Daiichi Sankyo, Incyte, and Novartis.
Elena Gabriela Chiorean, MD

Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Fred Hutchinson Cancer Research
Seattle, Washington

Elena Gabriela Chiorean, MD, has disclosed that she has received consulting fees from Bayer, BioNTech, Cardiff, Ipsen, Noxxon, Pfizer, and Stemline.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

On-demand video roundtable of global experts’ perspectives on optimal management of pancreatic cancer with PARP inhibitors, from Clinical Care Options (CCO)

Downloadable slideset on current advances in PARP inhibition in pancreatic cancer from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD person default Michel Ducreux, MD, PhD Philip Agop Philip, MD, PhD, FRCP Released: December 14, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings